Chronic Hepatitis C, Insulin Resistance and Vascular Disease

被引：6

作者：

Trpkovic, Andreja ^{[1
]}

Stokic, Edith ^{[2
]}

Radak, Djordje ^{[3
,4
]}

Gluvic, Zoran ^{[5
]}

Haidara, Mohamed ^{[6
]}

Mikhailidis, Dimitri P. ^{[7
]}

Isenovic, Esma. R. ^{[1
]}

机构：

[1] Inst Vinca, Lab Mol Genet & Radiobiol, Belgrade 11001, Serbia

[2] Inst Internal Med, Dept Endocrinol Diabet & Metab Disorders, Novi Sad, Serbia

[3] Dedinje Cardiovasc Inst, Dept Vasc Surg, Belgrade, Serbia

[4] Univ Belgrade, Sch Med, Belgrade, Serbia

[5] Univ Hosp Zemun, Dept Endocrinol, Belgrade, Serbia

[6] King Khalid Univ, Coll Med, Dept Physiol, Abha, Saudi Arabia

[7] UCL, Sch Med, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2010年 / 16卷 / 34期

关键词：

Hepatitis C; insulin resistance; interferon-alpha; vascular disease; PEGINTERFERON PLUS RIBAVIRIN; ACTIVATED-RECEPTOR-ALPHA; CHRONIC VIRAL-HEPATITIS; PROTEIN PHOSPHATASE 2A; FATTY LIVER-DISEASE; DEPENDENT DIABETES-MELLITUS; NECROSIS-FACTOR RECEPTORS; INDEPENDENT RISK-FACTOR; VIRUS CORE PROTEIN; COMBINATION THERAPY;

D O I：

10.2174/138161210794455067

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.

引用

页码：3823 / 3829

页数：7

共 50 条

[1] Insulin resistance in chronic hepatitis C
Yazicioglu, G
Isitan, F
Altunbas, H
Suleymanlar, I
Ozdogan, M
Balci, MK
Karayalcin, U
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (11) : 1020 - 1022
[2] Insulin resistance and chronic hepatitis C
Tkachenko, L. I.
Maleev, V. V.
TERAPEVTICHESKII ARKHIV, 2016, 88 (11) : 29 - 36
[3] Adipokines and insulin resistance in chronic hepatitis C
Tsochatzis, Emmanuel
Papathfodoridis, George V.
Archimandritis, Athanasios J.
HEPATOLOGY, 2007, 46 (06) : 2050 - 2051
[4] Insulin resistance and steatosis in chronic hepatitis C
Machado, Mariana V.
Cortez-Pinto, Helena
ANNALS OF HEPATOLOGY, 2009, 8 : S67 - S75
[5] Pathomechanism of insulin resistance in chronic hepatitis C
Kukla, Michal
Sawczyn, Tomasz
Zwirska-Korczala, Krystyna
Jarosz, Miroslaw
PRZEGLAD GASTROENTEROLOGICZNY, 2011, 6 (05): : 284 - 289
[6] Adipokines and insulin resistance in chronic hepatitis C - Reply
Cua, Ian Homer Y.
George, Jacob
HEPATOLOGY, 2007, 46 (06) : 2051 - 2051
[7] DEGREE OF CHRONIC HEPATITIS C SEVERITY AND INSULIN RESISTANCE
Ibrahim, Abdul Razak Kelana
Setiawan, Poernomo Boedi
Soelistijo, Soebagijo Adi
Nusi, Iswan Abbas
Maimunah, Ummi
Purbayu, Herry
Kholili, Ulfa
Widodo, Budi
Thamrin, Husin
Miftahussurur, Muhammad
Vidyani, Amie
NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (01): : 27 - 34
[8] The insulin resistance of chronic hepatitis C is peripheral and not hepatic
Milner, Kerry-Lee
Chisholm, Donald J.
Jenkins, Arthur B.
Trenell, Michael I.
Van der Poorten, David
Fragomeli, Vincenzo
Weltman, Martin
Hui, Jason
Dore, Greg
Zekry, Amany
George, Jacob
DIABETES, 2008, 57 : A20 - A21
[9] Molecular mechanisms of insulin resistance in chronic hepatitis C
Douglas, Mark W.
George, Jacob
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (35) : 4356 - 4364
[10] Chemerin, vaspin and insulin resistance in chronic hepatitis C
Kukla, M.
Zwirska-Korczala, K.
Gabriel, A.
Waluga, M.
Warakomska, I.
Szczygiel, B.
Berdowska, A.
Mazur, W.
Wozniak-Grygiel, E.
Kryczka, W.
JOURNAL OF VIRAL HEPATITIS, 2010, 17 (09) : 661 - 667

← 1 2 3 4 5 →